<DOC>
	<DOCNO>NCT00481546</DOCNO>
	<brief_summary>A recombinant adeno-associated virus serotype 2 ( rAAV2 ) vector alter carry human RPE65 ( hRPE65 ) gene . This vector show restore vision animal model resemble human RPE65-associated Leber congenital amaurosis ( LCA ) , incurable retinal degeneration cause severe vision loss . The propose study open label , Phase I clinical trial subretinal rAAV2-CBSB-hRPE65 administration individual RPE65-associated retinal disease . Five cohort include trial . Cohorts 1 , 2 4 consist individual 18 year age old . Cohorts 3 5 consist individual age 8 17 , inclusive . Enrollment Cohorts 3 5 begin confirm safety rAAV2-CBSB-hRPE65 administration old group participant . This trial lead great understanding safety thereby potential value gene transfer RPE65-associated retinal disease implication form retinal degenerative disease amenable type intervention . The goal clinical trial determine safety uniocular subretinal administration rAAV2-CBSB-hRPE65 individual RPE65-associated retinal disease . Ocular systemic toxicity assess prior follow vector administration determine adverse change may associate vector administration .</brief_summary>
	<brief_title>Phase I Trial Gene Vector Patients With Retinal Disease Due RPE65 Mutations</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<criteria>RPE65associated retinal disease ( two diseasecausing RPE65 mutation ) ; Clinical diagnosis Leber congenital amaurosis ( LCA ) /earlyonset retinal degeneration ( EORD ) severely impaired visual retinal function , best correct visual acuity 20/40 worse study eye ; Ability perform test visual retinal function ; Visible photoreceptor layer standard OCT scan ; Good general health ; Ability comply research procedure ; Specific Cohorts 1 , 2 4 : 18 year age older ; Specific Cohorts 3 5 : Between 8 17 year age , inclusive . AAV antibody titer great two standard deviation normal baseline ; Humoral immune deficiency evidence low tetanus toxoid IgG antibody titer ; Preexisting eye condition would preclude plan surgery interfere interpretation study endpoint surgical complication ; Complicating systemic disease ; Use antiplatelet agent may alter coagulation within 7 day prior study agent administration ; Use immunosuppressive medication ; Pregnancy breastfeeding ; Individuals ( male female ) childbearing potential unwilling use effective contraception ; Any condition would prevent subject complete followup examination course study ; Any condition make subject unsuitable study ; Current , recent participation , research protocol involve investigational agent therapy ; Recent receipt investigational biologic therapeutic agent .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leber congenital amaurosis</keyword>
	<keyword>LCA</keyword>
	<keyword>RPE65</keyword>
	<keyword>Retinal disease due RPE65 mutation</keyword>
	<keyword>RPE65-associated Leber congenital amaurosis</keyword>
</DOC>